AI assistant
GlaxoSmithKline PLC — Remuneration Information 2019
Nov 26, 2019
5262_rns_2019-11-26_fa118e78-4e2b-4a2f-9f79-f2bba262c564.html
Remuneration Information
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 7382U
GlaxoSmithKline PLC
26 November 2019
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 November 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan | |||
| Period of return: | From: | 1 May 2019 | To: | 31 October 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 153,724 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 0 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 153,724 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 November 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares | |||
| Period of return: | From: | 1 May 2019 | To: | 31 October 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 1,265,008 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 429,913 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 835,095 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 November 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline 2009 Share Option Plan - ADS | |||
| Period of return: | From: | 1 May 2019 | To: | 31 October 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 5,911,296 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 519,880 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 5,391,416 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 26 November 2019
| Name of applicant: | GlaxoSmithKline plc | |||
| Name of scheme: | GlaxoSmithKline plc Share Save Plan 2012 | |||
| Period of return: | From: | 1 May 2019 | To: | 31 October 2019 |
| Balance of unallotted securities under scheme(s) from previous return: | 2,326,896 | |||
| Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 0 | |||
| Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): | 181,084 | |||
| Equals: Balance under scheme(s) not yet issued/allotted at end of period: | 2,145,812 | |||
| Name of contact: | Victoria Whyte |
| Telephone number of contact: | 020 8047 5000 |
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
BLRKMMZMDVFGLZM